Facing Egg Shortage, Americans Bring Chickens Home to Roost

Hens for sale roam in their cage at Wabash Feed & Garden store in Houston, Texas, on February 10, 2025. AFP
Hens for sale roam in their cage at Wabash Feed & Garden store in Houston, Texas, on February 10, 2025. AFP
TT

Facing Egg Shortage, Americans Bring Chickens Home to Roost

Hens for sale roam in their cage at Wabash Feed & Garden store in Houston, Texas, on February 10, 2025. AFP
Hens for sale roam in their cage at Wabash Feed & Garden store in Houston, Texas, on February 10, 2025. AFP

A Houston poultry supply company is selling chickens like there is no tomorrow, as sky-high prices for eggs prompt some Americans to produce their own at home.

A recent US outbreak of bird flu since early 2024 is exacting a heavy toll on poultry farms. More than 21 million egg-laying hens have been "depopulated" this year so far, after 13.2 million were culled in December, according to the US Department of Agriculture.

Eggs, as a result, are a precious commodity these days.

John Berry, who manages a livestock company in Houston, reported a dramatic increase in demand for chickens as consumers grapple with the egg shortage.

"Our sales for poultry have doubled or maybe potentially tripled. I mean we're selling 100 chickens a week or more," Berry told AFP.

In times of egg abundance it would take two or three weeks to sell that many birds, he said.

A dozen premium eggs can now cost an eye-popping $10 in some US supermarkets, with even lower-grade ones now drawing twice their usual price of what is normally between two and three dollars.

The popular grocery store chain Trader Joe's is limiting purchases to one dozen eggs of any kind per household per day, and Costco is also limiting purchases.

Waffle House restaurants have slapped a 50-cent surcharge on each egg in a dish to compensate for higher costs.

Last week in Seattle, a restaurant was robbed of 500 eggs from its storeroom in the middle of the night.

- ' I have a large family' -

Berry said most of his chicken buyers are new to the world of egg production.

Such is the case of Arturo Becerra, who recently bought 10 hens for $400, with another $20 for a month's worth of feed.

On Monday, he bought five more hens, and plans to get another 10, "because I have a large family." His hens are still young and need a few more weeks to start laying eggs.

Some cities and towns in Texas allow people to raise chickens at home if they follow certain health norms.

The US Centers for Disease Control and Prevention (CDC) say the risk to the general public from avian flu remains "low," but has released safety guidelines for owners of backyard bird flocks.

The CDC also says that "people with job-related or recreational exposures to birds or other H5 virus-infected animals, are at greater risk of infection."

That has not appeared to deter Becerra.

"Now I have some place to put them, and besides, eggs are very expensive," said Becerra, a 57-year-old man who was born in Mexico. "I think it will be cheaper to buy hens and raise them."

Billy Underhill, the 62-year-old owner of a construction company and longtime chicken raiser, has bought two more of the clucking creatures.

"I just heard someone yesterday say that eggs were, like, 10 dollars a dozen," he said.

"I was already planning on buying a couple more chickens. I buy a couple every couple months because some of them die. Eventually they die and they stop laying so I'm going to keep the flow of eggs going in my family," he said.

Berry said there are no chickens to replace the millions that had to be killed because of avian influenza.

"You have to have had anticipated this and raised a thousand extra chickens or a million extra chickens," said Berry.

In the United States, the disease is affecting not just poultry farms but also dairy cows.

There have been 68 cases among people since early last year, with one of them fatal. Most of them were among people coming into contact with infected animals, according to the CDC.

The man who died was infected "after exposure to a combination of a non-commercial backyard flock and wild birds," health authorities said.

Berry said there is a generation of chickens growing and waiting to replace the ones who were destroyed. But it will take time, and as eggs store well, he recommends that people stock up.

"It'll be a couple of months, I would guess at the soonest. Seems like it's two or three months or more before things kind of get right."



Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
TT

Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP

It's been dubbed the "Arc de Trump." But now President Donald Trump's latest building project has an official name -- the "United States Triumphal Arch."

White House Press Secretary Karoline Leavitt revealed the formal title on Wednesday, saying the giant structure was being built to mark the 250th anniversary of US independence, AFP reported.

"In honor of this historic occasion, President Trump and the Department of Interior will submit plans for the United States Triumphal Arch," Leavitt told reporters.

Showing off a picture that she initially held upside down, Leavitt said the "monumental" arch would stand 250 feet (76.2 meters) tall "in honor of 250 years."

Its colossal height, including a huge golden Lady Liberty statue on top, means it will dwarf perhaps its most famous predecessor, the Arc de Triomphe in Paris, which stands at 164 feet.

In fact it is set to be the largest structure of its kind in the world, pipping Mexico City's Monument to the Revolution and knocking Pyongyang's Arch of Triumph to third place.

Plans for the arch were first revealed in October when AFP journalists spotted a model on Trump's desk in the Oval Office, after which it was quickly dubbed the "Arc de Trump" by US media.

Trump revealed the first full renderings for the structure last Friday.

The arch is one of several architectural projects -- including the construction of a gigantic White House ballroom and renovations to the Kennedy Center for the Performing Arts -- that Trump has undertaken to leave a mark on Washington in his second term.

Critics say the gold-accented arch, which will tower over the 99-foot-tall Lincoln Memorial, is a monument to the 79-year-old Trump's vanity.

The arch will partly be funded by US taxpayers, getting $2 million in special funds from the US National Endowment for the Humanities, with up to $13 million in funds to match any donations, ABC News reported.

But Leavitt said it was aimed at celebrating US national pride.

"Long after everyone in this room is gone, our children and grandchildren will remain inspired by this national monument," she told reporters.


Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
TT

Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File

Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.

The review by the Cochrane organization -- which is considered the gold standard for analyzing existing evidence -- looked at drugs that target a plaque called amyloids which builds up in the brains of Alzheimer's patients.

Researchers have long sought a way to eliminate this plaque, believing it could be the cause of the most common form of dementia which affects millions of elderly people every year, said AFP.

After decades of costly yet unsuccessful research, two anti-amyloid drugs called lecanemab and donanemab were initially hailed as gamechangers that finally offered a way to slow the progress of the debilitating disease.

Both drugs were approved by the United States and European Union over the last few years.

However concerns about their effectiveness, cost and side effects including an increased risk of brain swelling and bleeding have since prompted caution. State-run health services in the UK and France have refused to cover the drugs.

The new Cochrane review combined data from 17 clinical trials that included a total of more than 20,000 people with mild cognitive impairment or early dementia.

The trials, which took place over roughly 18 months, studied seven different anti-amyloid drugs.

Only one of the trials examined donanemab -- sold under the name Kisunla by US pharma giant Eli Lilly -- while one studied lecanemab, sold as Leqembi by Biogen and Eisai.

While early trials suggested these drugs made a statistically significant difference, this did not translate into "something clinically meaningful for patients," lead study author Francesco Nonino of Italy's IRCCS institute told a press conference.

Brain scans showed that the drugs successfully removed amyloids, the researchers emphasized.

This means "the idea that removing amyloids will benefit patients was refuted by our results," said study co-author Edo Richard of Radboud University Medical Center in the Netherlands.

- 'Not delivering on promise' -

Richard, who has previously expressed skepticism about anti-amyloid drugs, said he hopes efforts targeting other mechanisms that potentially cause Alzheimer's lead to more effective drugs in the future.

British biologist John Hardy, who first developed the amyloid hypothesis in the 1990s, criticized the review for lumping together data about lecanemab and donanemab along with drugs that are known to be ineffective, therefore dragging down the overall average.

"This is a silly paper which should not have been published," Hardy told AFP, disclosing that he has consulted for Eli Lilly, Biogen and Eisai.

In response to such questions, Richard said that while the drugs included in the study may work in different ways, they all have the same target: amyloid beta proteins.

Australian neuroscientist Bryce Vissel, who was not involved in the research, said it "does not prove amyloid has no role in Alzheimer's, and it does not rule out future amyloid-directed therapies that may yet help patients".

"But it does show that the current generation of anti-amyloid drugs is not delivering the promise that has surrounded it."


Indonesia Police Arrest Six for Komodo Dragon Smuggling

A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
TT

Indonesia Police Arrest Six for Komodo Dragon Smuggling

A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)
A komodo dragon is displayed by nature and conservation agency officials and police officers after being seized from suspects attempting to smuggle it into Thailand, during a press conference at the regional police headquarters in Surabaya on April 15, 2026. (Photo by JUNI KRISWANTO / AFP)

Indonesian authorities said Wednesday they have arrested six people allegedly involved in smuggling endangered Komodo dragons native to the archipelago and destined for Thailand.

Two suspects were arrested in February in the port city of Surabaya on the east coast of Java island as they got off a ship with three live Komodo dragons -- the world's largest living lizard.

Further investigation led to four more arrests in the weeks that followed, AFP reported.

Police said the animals had been obtained from "suppliers or hunters" in Indonesia's East Nusa Tenggara province, where they are native to a handful of small islands.

The suspects are accused of buying the dragons for 5.5 million rupiah (about $320) apiece and selling them for six times the price, apparently to be shipped to clients in Thailand.

According to East Java police, the suspects have smuggled and traded at least 20 Komodo dragons since January last year, and pocketed some $33,000.

They face up to five years in prison and a fine.

The International Union for Conservation of Nature lists the Komodo dragon as endangered, with a global population of about 3,400, including juveniles.

The fearsome reptiles, which can grow to three meters (10 feet) in length and weigh up to 90 kilograms (200 pounds), are threatened by human activity and by climate change destroying their habitat.

Poachers collect them to be sold as pets or display animals.

Komodo dragons in the wild are found only in Indonesia's World Heritage-listed Komodo National Park and on neighboring Flores island.

Police said Wednesday they had also arrested two suspects for smuggling 140 kilograms of pangolin scales from the northwestern province of Riau to Surabaya.

Pangolins are among the world's most endangered species, and their scales are prized in countries like China and Vietnam, where they are used in traditional remedies even though they provide no scientifically proven medicinal benefit.